cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Horizon Therapeutics Public Ltd Co
15 own
24 watching
Current Price
$0
$0.09
(0.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
22,725.06M
52-Week High
52-Week High
113.83
52-Week Low
52-Week Low
57.84
Average Volume
Average Volume
0.13M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
47.3668
iconMarket Capitalization22,725.06M
icon52-Week High113.83
icon52-Week Low57.84
iconAverage Volume0.13M
iconDividend Yield--
iconP/E Ratio47.3668
What does the Horizon Therapeutics Public Ltd Co do?
Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More
How much money does Horizon Therapeutics Public Ltd Co make?
News & Events about Horizon Therapeutics Public Ltd Co.
Business Wire
1month ago
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 randomized placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7...
Business Wire
1month ago
Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS...
Business Wire
1month ago
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease activity...
Zolmax
1month ago
StockNews.com started coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP Get Rating) in a report published on Wednesday. The firm issued a buy rating on the biopharmaceutical companys stock. Horizon Therapeutics Public Price Performance Shares of NASDAQ:HZNP opened at $111.86 on ...
Business Wire
1month ago
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indications and Usage section of the TEPEZZA label to specify its use for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or...
Frequently Asked Questions
Frequently Asked Questions
What is Horizon Therapeutics Public Ltd Co share price today?
plus_minus_icon
Can Indians buy Horizon Therapeutics Public Ltd Co shares?
plus_minus_icon
How can I buy Horizon Therapeutics Public Ltd Co shares from India?
plus_minus_icon
Can Fractional shares of Horizon Therapeutics Public Ltd Co be purchased?
plus_minus_icon
What are the documents required to start investing in Horizon Therapeutics Public Ltd Co stocks?
plus_minus_icon
What is today’s traded volume of Horizon Therapeutics Public Ltd Co?
plus_minus_icon
What is today’s market capitalisation of Horizon Therapeutics Public Ltd Co?
plus_minus_icon
What is the 52-Week High and Low Range of Horizon Therapeutics Public Ltd Co?
plus_minus_icon
What percentage is Horizon Therapeutics Public Ltd Co down from its 52-Week High?
plus_minus_icon
What percentage is Horizon Therapeutics Public Ltd Co up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.09
(0.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.54
$-0.12 (-0.28 %)
Catalent, Inc.
Catalent, Inc.
$39.83
$0.00 (0.00 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$58.11
$1.41 (2.49 %)
United Therapeutics Corporation
United Therapeutics Corporation
$227.00
$0.50 (0.22 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$41.54
$-0.12 (-0.28 %)
Catalent, Inc.
Catalent, Inc.
$39.83
$0.00 (0.00 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$58.11
$1.41 (2.49 %)
United Therapeutics Corporation
United Therapeutics Corporation
$227.00
$0.50 (0.22 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00